Novo Nordisk's (NVO) stock jumped more than 7% in pre-market trading Wednesday after beating Wall Street's profit estimates for the first quarter, and despite a slight cut to its sales forecast for the year. Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.BAGSVæRD, DENMARK - 2025/03/27: A view of the logo of Novo Nordisk A/S at the headquarters in Bagsværd. Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. (Photo by Kristian Tuxen Ladegaard Berg/SOPA Images/LightRocket via Getty Images)·SOPA Images via Getty Images Wegovy sales came in at $2.6 million, 7% below Wall Street's consensus, meanwhile Ozempic sales for the quarter were $4.9 million, or about 3% ahead of estimates. Pressure on Wegovy sales could ease as the company sees slowing of compounded copies of the weight loss drug, after the FDA confirmed the shortage was over earlier this year. The drug has been losing market share to competitor Eli Lilly's (LLY) Zepbound in the U.S. Still, CEO Lars Fruergaard Jørgensen said on an earnings call Wednesday morning that despite that slowdown, Novo Nordisk holds about 72% of the global obesity and diabetes GLP-1 market share. NYSE - Delayed Quote•USD (NVO) Follow View Quote Details 66.29 - (-4.09%) At close: May 6 at 4:00:02 PM EDT Advanced Chart "We have launched Wegovy in 25 countries, including three in that last month, reflecting greater supply availability," Jørgensen said. Novo has engaged in a number of deals in the past month that would increase access to the drug in the U.S., including relationships with telehealth platforms like Hims & Hers (HIMS), and being named the preferred drug on CVS (CVS) formulary. The latter sent Lilly's stock diving last week. Jørgensen said the CVS deal would only serve a fraction of the market and was "not really about gaining a share short-term." Novo cut sales guidance for the year by 3%, now estimating 13%-21%, compared to previous guidance of 16% to 24%. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. For the latest earnings reports and analysis, earnings whispers and expectations, and company earnings news, click here Read the latest financial and business news from Yahoo Finance View Comments
Novo Nordisk beats on Q1 earnings, cuts 2025 outlook
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...